ArticleScientific reports2026
Exploring the characteristics of gut microbiome changes in lung cancer patients and healthy controls.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is among the most prevalent and lethal malignant neoplasms worldwide. Although the role of the pulmonary microbiome in the pathogenesis of lung cancer has been examined, the structure, diversity, and composition of the gut microbiome in lung cancer remain largely unclear. The present study is chiefly concerned with the analysis of the characteristics and alterations of the gut microbiome in lung cancer patients and healthy individuals, and with the exploration of potential characteristic gut microbiome in lung cancer patients. Stool samples were collected from 40 patients with lung cancer and 20 healthy controls at the Lung Cancer Center of West China Hospital, Sichuan University. The samples were analysed using 16S rRNA gene amplicon sequencing to investigate differences in the relative and absolute abundance, diversity, and functionality of the gut microbiome between the two groups. The predominant gut microbiome communities in lung cancer patients and healthy controls were found to comprise Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria. The F/B (Firmicutes/Bacteroidetes) ratio in the lung cancer group (0.73) was lower than that in the healthy control group (0.96). We found that there was no significant difference in α-diversity between LC patients and the control group (p > 0.05), whereas β-diversity of the gut microbiome revealed differences in microbial community structure between the patient and control groups (stress < 0.2). The healthy controls exhibited higher abundances of Bacteroidetes and Firmicutes as dominant bacterial groups, whereas the characteristic bacterial groups in lung cancer patients were the Ruminococcus_gnavus_group and the Prevotellaceae NK3B31 group. Studies have demonstrated that the gut microbiome of patients with lung cancer patients undergoes changes, and characteristic gut microbiome profiles may serve as potential diagnostic markers for lung cancer. Furthermore, we have revealed that impairments in normal gut microbiome function may be associated with the development and progression of lung cancer, providing valuable insights for the early prevention, diagnosis, and targeted intervention of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.